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1042-84 Elevated Plasma Level of Placental Growth Factor Is 
Correlated With Peripheral Monocyte Fraction in 
Patients With Acute Myocardial Infarction
Hajime Iwama, Shiro Uemura, Noriyuki Naya, Keiichi Imagawa, Minoru Takaoka, Hiroyuki 
Kawata, Manabu Horii, Tamio Nakajima, Nofumi Doi, Yoshihiko Saito, Nara Medical 
University, Kashihara City, Nara, Japan
Background: Earlier studies have revealed that bone mallow derived stem cells (BMSM)
participate in wound healing and regeneration of infarct tissue in acute myocardial infarc-
tion (AMI). However, it remains unknown how infarct heart tissue stimulates and recruits
BMSC to the heart. Placental growth factor (PlGF), a member of vascular endothelial
growth factor (VEGF) family, exerts its angiogenic property through binding to VEGF
receptor-1. Furthermore, PlGF has been reported to induce BMSC peripheral mobiliza-
tion. In this study, we studied the serial changes of plasma PlGF levels and white blood
cell profile after AMI in human, and also studied the tissue expression of PlGF in the inf-
arct myocardium of mouse AMI model. Method and results: Thirty five AMI patients AMI
(67.5 y/o) were enrolled, and plasma cytokine levels were measure by ELISA. The
plasma PlGF levels of AMI patients significantly increased compared to those in age-
matched controls (36.8+/-31.9, 13.3+/-5.2 pg/ml, p<0.0001). Monocyte fraction was ele-
vated in AMI peripheral blood from 3rd to 7th day of AMI, and PlGF positively correlated
to peak monocyte fraction (r= 0.496, p<0.005), while PlGF did not correlate to polymor-
phic neutrophil fraction. Plasma levels of VEGF and stem cell factor also elevated in AMI
than control, but they did not correlate to monocyte fraction. In the AMI mouse model,
quantitative real time PCR revealed that PlGF mRNA expression was significantly (26.6
+/-5.2 times, p<0.001) increased in infarct heart compared with sham operated heart on
3rd surgical day. Furthermore, immunohistochemical staining showed that PlGF protein
was overexpressed mainly in vascular tissue in infarct region, but scarcely in non-infarct
region. Vascular expression of PlGF protein was not detected in sham-operated heart.
Conclusion: The present study demonstrates that plasma PlGF levels are increased in
AMI patients, and correlated with cell number of monocyte fraction, and PlGF mRNA and
protein are over-expressed in vascular tissue at the site of infarct myocardium. Elevated
plasma PlGF might have effect on the recruitment of monocyte, as well as vascular pro-
genitor cells, from bone marrow to peripheral circulation.
1042-85 Tumor Necrosis Factor-α Blockade: A Key Inhibition to 
Modulate the Inflammatory Response in Patients With 
Unstable Angina?
Vittoria Rizzello, Giovanna Liuzzo, Luigi M. Biasucci, Salvatore Brugaletta, Graziana 
Trotta, Annabella Procoli, Sonia Iacovella, Antonino Buffon, Antonio G. Rebuzzi, Filippo 
Crea, The Catholic University of the Sacred Heart, Rome, Italy
Background: Tumor necrosis factor-α (TNF-α ) is a pro-inflammatory cytokine increased
in unstable angina (UA). TNF-α activates NF-kB and favours the expansion of
CD4+CD28null T-cells, an aggressive and rare pro-inflammatory lymphocyte subset, fre-
quently observed in UA. We used Infliximab, a monoclonal antibody against TNF-α , to
modulate in vitro the inflammatory response in patients with UA.
Methods: Peripheral blood samples were collected from 17 patients with UA (Braun-
wald’s class IIIB). The monocyte production of TNF-α was assessed after 4 hours incu-
bation with lipopolysaccharide (LPS 1ng/mL) and after incubation with LPS (1ng/m) plus
Infliximab (0.1, 1, 10 and 100 µg/mL). TNF-α levels were measured by ELISA. The mod-
ulation of CD4+CD28null T- cell frequency by Infliximab was assessed with flow cytometry
after 24 hours incubation of whole blood with and without Infliximab (0.1, 1, 10 and 100 µ
g/mL).
Results: TNF-α production significantly increased after incubation with LPS (median)
(from 0 to 266.3 pg/ml, P=0.03) but was reduced to 0.43 pg/ml by 0.1 µ g/mL of Infliximab
(P=0.001) and totally inhibited by higher doses . CD4+CD28null T-cell frequency was
reduced from 6.2% to 4.9%, 4.5% and 4.1% after incubation with 1, 10, and 100 µ g/mL
of Infliximab, respectively (see figure; P<0.05 by ANOVA).
Conclusion: In UA, monocyte production of TNF-α and the frequency of CD4+CD28null
T-cells are reduced by Infliximab. These results may introduce novel anti-inflammatory
strategies for the treatment of UA. 
1042-86 Risk Stratification in ST-Segment Elevation Myocardial 
Infarction With Multiple Biomarkers
Eli V. Gelfand, David A. Morrow, Marc S. Sabatine, Nader Rifai, Sabina A. Murphy, 
Carolyn McCabe, Elliott M. Antman, for the TIMI Study Group, Beth Israel Deaconess 
Medical Center, Boston, MA, Harvard Medical School, Boston, MA
Background: Among patients with STEMI, cardiac troponin, B-type natriuretic peptide
and C-reactive protein independently predict adverse cardiac events. However, their util-
ity in combination remains untested. We hypothesize that in patients with STEMI under-
going fibrinolysis, simultaneous assessment of BNP, CRP and troponin I on admission
provides useful complementary information with respect to short-term mortality.
Methods: In ENTIRE-TIMI 23 trial, 483 patients with STEMI <6 hours from symptom
onset were treated with either TNK or combination of half-dose TNK plus abciximab, and
with either unfractionated heparin or enoxaparin. We evaluated the relationship between
the number of elevated biomarkers and mortality at 30 days among 443 patients, in
whom samples for measurement of all three biomarkers were available.
Results: Mortality by 30 days increased in proportion to the number of elevated biomark-
ers, revealing an 18-fold gradient between those with 3 versus none of the biomarkers
elevated (P<0.001) (Fig). There was a trend towards more new CHF by 30 days in
patients with more elevated biomarkers (P=0.14). Number of patients with either death or
CHF by 30 days was also directly proportional to the number of elevated biomarkers
(P<0.001).
Conclusion: Among patients with STEMI, a multimarker approach combining CRP, BNP
and TnI provides incremental information regarding short-term mortality risk. Such an
approach may prove useful for enhancing clinical decision-making in this population.
1042-87 White Blood Cell Count Predicts Angiographic Findings 
in Patients With Acute Coronary Syndromes
Jose L. Navarro Estrada, Alfredo Hirschson Prado, Cecilia Bahit, Fernando Botto, Jose 
Gabay, Jose Alvarez, Luis Guzman, Hospital Italiano de Buenos Aires, Buenos Aires, 
Argentina
Elevation of inflammatory markers has been associated with adverse outcome in patients
with acute coronary syndromes. We sought to assess the relation between baseline
white blood cells (WBC) count and angiographic findings and outcome in patients with
non-ST elevation acute coronary syndromes.
Methods: We evaluated the relation between baseline WBC count, angiographic findings
and outcome in 590 patients in a cohort of 1293 consecutive patients with acute coronary
syndromes. Angiograms were read by two independent readers blinded to patient data.
We grouped the WBC count into low (<25th percentile), intermediate ( 25th-75th percen-
tile) and high (>75th percentile).
Results: Baseline WBC count ranged from 3530 to 35800, and the median was 9300
(25th-75th 7700-11500). Patients with high WBC count were older, more likely to be male
and had more frequently history of hypertension and diabetes. Angiographic findings are
shown in the table. Higher WBC counts were associated with higher rates of angiograph-
ically thrombus, complicated plaque and extent of coronary artery disease. Likewise,
patients with high WBC count has 2 fold increase risk of death or myocardial infarction at
180 days compared with patients with low or intermediate WBC count (14.2% versus
7.5%, p=0.026).
Conclusions: In this study, elevation of white blood cells count was associated with more
extensive CAD, more complex coronary lesions and higher occurrence of death / myocar-
dial infarction at 180 days.
Angiographic findings
Low WBC Count
n=146
Intermediate WBC
n=293
High WBC Count
n=141
p
Complicated Plaque 36.3% 46.4% 51.1% 0.033
Thrombus present 11.0% 19.1% 23.4% 0.019
3-Vessels Disease 17.8% 25.0% 29.3% 0.070
